Edgewise Therapeutics Inc
Research Edgewise Therapeutics Inc (EWTX) on Bullrun: market cap USD 4.76B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEWTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.76B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 57.33M
- Free cash flow-USD 42.50M
Valuation Snapshot
latest market cap is USD 4.76B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 167.80K | -USD 144.07M | n/a | -1.63 | USD 61.15M | USD 3.99M | USD 522.26M |
| FY2024 | USD 0 | -USD 133.81K | -USD 110.34M | n/a | -1.45 | USD 41.67M | USD 4.74M | USD 459.22M |
| FY2023 | n/a | -USD 100.16K | -USD 97.69M | n/a | -1.57 | USD 86.10M | USD 5.41M | USD 318.83M |
| FY2022 | n/a | -USD 67.64M | -USD 58.18M | n/a | -1.26 | USD 21.99M | USD 66.00K | USD 346.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.76B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.64B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.53B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 694.27M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 565.13M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 756.36M | n/a | n/a | n/a |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Edgewise Therapeutics Inc's market cap?
Edgewise Therapeutics Inc's market capitalization is USD 4.76B.
What does Edgewise Therapeutics Inc do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.